Innovation in oncology is facing a significant hurdle when it comes to identifying novel targets, this is the belief of Germany and Switzerland-based DISCO Pharmaceuticals, which plans to overcome the obstacle with its surfaceome technology. DISCO’s technology identifies protein communities on the surface of cancer cells to expand the molecular target space.The company was co-founded in 2022 by Roman Thomas, Johannes Heuckmann, Bernd Wollscheid and Julien Sage. Thomas and Heuckmann previously worked together at the University of Cologne. They also previously founded another biotech startup. “We understood, in the early days of precision medicine, that there was a clear opportunity to take this technology into clinical application for personalized intervention,” said Thomas, who is DISCO’s CEO.
“We understood, in the early days of precision medicine, that there was a clear opportunity to take this technology into...
